论文部分内容阅读
目的评估3种不同的联合治疗对慢性乙型肝炎感染的临床疗效。方法慢性乙型肝炎患者120例平均分为3组,第1组为干扰素(INF-)α+乙肝疫苗组;第2组为INF+泛昔洛韦(FCV)组;第3组为INF+拉米夫定(3TC)组,分别治疗6个月。结果(1)治疗后丙氨酸氨基转移酶(ALT)复常率无差异。(2)治疗后第3组乙肝E抗原阴转率和HBV DNA的阴转率明显高于其他两组,差异有统计学意义。而第1、2组间的比较差异无统计学意义。结论拉米夫定与干扰素联合治疗对HBV的抑制作用明显优于其他两种方法。
Objective To evaluate the clinical efficacy of three different combination therapies for chronic hepatitis B infection. Methods One hundred and twenty patients with chronic hepatitis B were divided into three groups on average, the first group was IFN-α + hepatitis B vaccine group, the second group was INF + famciclovir (FCV) group and the third group was INF + lamivudine (3TC) group, respectively, for 6 months. Results (1) There was no difference in the normalization rate of alanine aminotransferase (ALT) after treatment. (2) After treatment, the negative conversion rate of hepatitis B E antigen and HBV DNA negative rate in the third group were significantly higher than the other two groups, the difference was statistically significant. However, the difference between groups 1 and 2 was not statistically significant. Conclusion The combination of lamivudine and interferon is superior to the other two methods in inhibiting HBV.